Last reviewed · How we verify
NCT02798965: GPCBasedow
Prevalence of Circulating Parvovirus Genome in Recently Diagnosed Graves' Disease: a Case-control Study
NA trial testing serodiagnosis in Graves Disease in 52 participants. Completed in 1 May 2014.
1 May 2014
Quick facts
| Lead sponsor | Centre Hospitalier Universitaire, Amiens |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 52 |
| Start date | 1 December 2010 |
| Primary completion | 1 May 2014 |
| Estimated completion | 1 May 2014 |
| Sites | 1 location across France |
Drugs / interventions tested
- serodiagnosis — full drug profile →
Conditions studied
- Graves Disease — all drugs for Graves Disease →
Sponsor
Centre Hospitalier Universitaire, Amiens
Who can join
Adults 18 to 99, any sex, with Graves Disease. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
prevalence of circulating parvovirus genome
Time frame: Day 0
Sponsor's own description
Lymphocytic thyroiditis is the most common autoimmune disease, usually affecting young women. Although the aetiology and pathogenesis remain obscure, the most widely accepted hypothesis is an interaction between a genetic predisposition and an environmental trigger factor such as viral infection. Parvovirus infections have been proposed as trigger factors for Hashimoto's thyroiditis and Graves' disease.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT02798965
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Graves Disease
Currently open trials in the same condition.
- NCT07480720 — Systemic Inflammation, Thyroid Autoimmunity and Neuroretinal Changes in Graves Disease · recruiting
- NCT07305818 — NEXUS Study: A Study to Test Single and Multiple Doses of MER511 Given to Adults With Graves' Disease · Phase 1 · recruiting
- NCT07286656 — A Study of GensSci098 in Subjects With Graves' Disease · Phase 1 · recruiting
- NCT07129642 — Allogeneic Anti-CD19 CAR-T for Refractory Graves' Disease · EARLY_PHASE1 · recruiting
- NCT07369063 — Impact of Vitamin D Therapy on Thyroid Function and Antibody Levels in Pediatric Graves' Disease · Phase 2 · recruiting
Other Centre Hospitalier Universitaire, Amiens trials
Trials by the same sponsor.
- NCT07354568 — Prognosis of Patients With Mixed Cardiogenic-Vasoplegic Shock · recruiting
- NCT07071662 — Induction of Labor in Breech Presentation · completed
- NCT06909487 — Clinical Characterization of Very and Extremely Preterm Infants Who Received Excess Erythrocyte Transfusions With Respec · completed
- NCT07037719 — Automatic Detection of Eligible Patients to RAUC Protocol (RAUCISABLE) · recruiting
- NCT06996145 — Study of the Isometry of the Anterior Cruciate Ligament From the Center of the Native MRI Insertion Reported on Dynamic · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02798965 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier Universitaire, Amiens
- Last refreshed: 17 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02798965.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing